Zachary Bornholdt | Chief Executive Officer
Eitr Biologics

Zachary Bornholdt, Chief Executive Officer, Eitr Biologics

Over the course of my career, I have accumulated over 20 years of experience spanning academia and industrial laboratories focused on antibody discovery, protein engineering and purification as well as immunotherapeutic development. I led the research and development program behind the first pan-ebolavirus immunotherapeutic MBP134, now under an active IND with the FDA and currently in clinical trials with funding support from the Biomedical Advanced Research and Development Authority (BARDA). My most recent work focused on antibody engineering to enhance efficacy through synergistic combinations of antibodies targeting unique epitopes through bispecific antibody design as well as examining the efficacy of immunotherapeutics in combination with vaccines and/or small molecule drugs. Together these studies suggested antibodies alone are unable to reach the level of therapeutic efficacy observed from either engineered synergistic bispecific antibodies or immunotherapeutics supplemented with small molecule treatments. I co-founded Eitr Biologics, Inc. with the goal of creating a novel platform technology to create next generation therapeutics for unmet public health needs. We believe our Orthogonal Dual-Interacting Nanotherapeutic (ODIN) bispecific scaffold will successfully capture the positive qualities of both a bispecific antibody (synergy, specificity, and safety profile) and small molecule (targeting cryptic epitopes and fast biodistribution rate).


Festival of Biologics Day 1 @ 10:00

Panel Discussion: Engineering Next Generation Therapeutics – the future of antibody development

  • Reviewing the current state of antibody therapeutics
  • Challenges in engineering next generation ADCs, multispecifics and mAbs
  • The potential of new modalities

Festival of Biologics Day 1 @ 17:10

The Orthogonal Dual-Interacting Nanotherapeutic (ODIN) platform for Next-generation Bispecifics

Current bispecific platforms primarily rely on an engineered IgG scaffold to achieve multispecificity. However, the large size of these biomolecules can significantly impede their biological activity owing to reduced biodistribution and tissue penetration. Furthermore, bispecific IgGs can have significant liabilities in manufacturability due to their inherent complexity and biophysical properties (e.g., stability and aggregability).  Finally, the need to manufacture IgG based bispecifics in mammalian cells substantially impacts cost of goods. To address these short comings of current bispecific antibody technologies Eitr Biologics, Inc. has developed a novel alternative technology, the Orthogonal Dual-Interacting Nanotherapeutic (ODIN) platform. The ODIN platform relies on Eitr’s proprietary VH framework modification that affords the insertion of orthogonal paratopes such as ‘stalk-and-knob’ structures derived from bovine ultralong CDR3 (UL-CDR3) sequences without disruption of native binding affinity of the original VH domain. This highly modular platform allows for the rapid development of a new class of small single-domain bispecific antibodies

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers